Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.55 |
| ▸ | KDM6B | O15054 | 1/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.55 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.55 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.54 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464238 | 1.00 | KDM4E (0.55) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL3790448 | 0.96 | CDK8 (0.54) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL3788730 | 0.89 | KDM4E (0.46) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL1646106 | 0.86 | JMJD6 (0.55) | CDK8JMJD6KDR | |
| SCHEMBL10819449 | 0.85 | CDK8 (0.50) | KDM4CCDK8KDRABL1PTGS2 | |
| SCHEMBL20476711 | 0.85 | KDM4E (0.58) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL1648927 | 0.82 | CDK8 (0.45) | KDM4ECDK8ALDH1A1KDRABL1 | |
| SCHEMBL29377304 | 0.80 | TUBB4A (0.58) | CDK8KDRABL1MAOB | |
| SCHEMBL103794 | 0.80 | TUBB4A (0.58) | CDK8KDRABL1MAOB | |
| SCHEMBL29141528 | 0.80 | KDM4E (0.58) | KDM4EKDM4CKDM6BKDM5CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023208103-A1 | COMPOUND CAPABLE OF BEING USED FOR GOUT | 江苏新元素医药科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116836154-A | Compounds useful for gout | 江苏新元素医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| EP-2467378-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG Life Sciences Ltd (KR) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | XDH, PNPO, AOX1 | KDM4E 2194/4885KDM4C 1968/4885KDM6B 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.